The Institute for Clinical and Economic Review (ICER) is in its third year of reviewing fair access to prescription drugs, but continues to face obstacles to doing a thorough assessment. Greater transparency is needed to make a clearer evaluation of consumers’ access to the drugs they are prescribed, the report – which deemed only two of 18 drugs included to be fairly priced and eligible for cost-sharing analysis – concludes.
Health Plan Transparency Still At Issue, ICER Finds
In its third annual report on fair access to prescription drugs, the US pricing watchdog found high concordance with some of its recommended policies, but thinks greater transparency is needed for a thorough assessment.
More from Drug Pricing
More from Scrip
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.
• By
DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.
• By
Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.